BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drug

BioMarin gains rights to a Fabry disease enzyme replacement therapy with potential dosing advantages over products from Sanofi and Chiesi Group. BioMarin’s new clinical-stage asset could reach patients ineligible for the Fabry drug that came with its Amicus Therapeutics acquisition earlier this year. The post BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting…

Read More

Ahead of Midterms, HFMA Calls for Cross-Sector Action on Healthcare Affordability

With healthcare affordability set to influence voters’ decisions in next week’s midterm elections, the Healthcare Financial Management Association is calling on healthcare leaders to move beyond finger-pointing and work together to address rising costs. HFMA is urging financial leaders across healthcare to sign its Declaration on Healthcare Affordability and Sustainability. The post Ahead of Midterms,…

Read More